Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Celldex Therapeutics Inc CLDX

Healthcare Biotechnology
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody... see more

Recent & Breaking News (NDAQ:CLDX)

Celldex Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 22, 2021

Celldex Appoints Freddy A. Jimenez, Esq. as Senior Vice President and General Counsel

GlobeNewswire January 4, 2021

Celldex Doses First Patient in Phase 1b Study of CDX-0159 in Chronic Inducible Urticaria

GlobeNewswire December 9, 2020

Celldex Therapeutics to Present at 3rd Annual Evercore ISI HealthCONx Conference

GlobeNewswire November 30, 2020

Celldex Presents Data from Oncology Portfolio at SITC 2020

GlobeNewswire November 9, 2020

Celldex Provides Corporate Update and Reports Third Quarter 2020 Results

GlobeNewswire November 5, 2020

Celldex Therapeutics Initiates Phase 1b Study of CDX-0159 in Chronic Spontaneous Urticaria

GlobeNewswire October 13, 2020

Celldex Therapeutics to Present at Upcoming Healthcare Conferences

GlobeNewswire September 10, 2020

Celldex Therapeutics Initiates Phase 1 Study of New Bispecific Product Candidate CDX-527 in Solid Tumors

GlobeNewswire August 24, 2020

Celldex Provides Corporate Update and Reports Second Quarter 2020 Results

GlobeNewswire August 6, 2020

Celldex to Report Second Quarter 2020 Financial Results and Host Corporate Update Call

GlobeNewswire August 3, 2020

Celldex Therapeutics Announces Closing of $150.0 Million Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire June 18, 2020

Celldex Therapeutics Announces Pricing of $130.4 Million Public Offering of Common Stock

GlobeNewswire June 15, 2020

Celldex Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire June 15, 2020

Celldex's KIT Inhibitor CDX-0159 Demonstrates Profound, Sustained Dose-dependent Reductions in Plasma Tryptase-an Indicator of Mast Cell Burden-and a Favorable Safety Profile

GlobeNewswire June 6, 2020

Celldex Provides Corporate Update and Reports First Quarter 2020 Results

GlobeNewswire May 6, 2020

Celldex Announces Acceptance of CDX-0159 Late-Breaking Poster Presentation with Voice Over at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2020

GlobeNewswire May 6, 2020

Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2019 Results

GlobeNewswire March 26, 2020

Celldex Therapeutics Announces $1.7 Million Milestone Payment from Rockefeller University Related to Collaboration on HIV Antibody Program

GlobeNewswire March 3, 2020

Celldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159

GlobeNewswire November 18, 2019